| Literature DB >> 30789347 |
Oscar Campos Lisboa1, Breno Bernardes-Souza1, Luiz Eduardo De Freitas Xavier1, Matheus Rocha Almeida1, Paulo César Rodrigues Pinto Corrêa1, Titus Josef Brinker2,3,4.
Abstract
BACKGROUND: Smoking is the largest preventable cause of mortality in Brazil. Education Against Tobacco (EAT) is a network of more than 3500 medical students and physicians across 14 countries who volunteer for school-based smoking prevention programs. EAT educates 50,000 adolescents per year in the classroom setting. A recent quasi-experimental study conducted in Germany showed that EAT had significant short-term smoking cessation effects among adolescents aged 11 to 15 years.Entities:
Keywords: medical students; prevention; schools; smoking; tobacco
Year: 2019 PMID: 30789347 PMCID: PMC6416894 DOI: 10.2196/12854
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Study design and flow of participants.
Smoking prevalence at baseline (t1) and at the 6- (t2) and 12-month (t3) follow-ups.
| Time pointa | Total sample, n (%) | Intervention group, n (%) | Control group, n (%) | Number needed to treat | ||||||
| t1 | 172/1353 (12.7) | 105/744 (14.1) | 67/609 (11.0) | |||||||
| t2 | 150/899 (16.7) | 64/472 (13.6) | 86/427 (20.1) | |||||||
| t3 | 243/1353 (18.0) | 116/744 (15.6) | 127/609 (20.9) | 19/12b | ||||||
| t1 | 97/757 (12.8) | 54/411 (13.1) | 43/346 (12.4) | |||||||
| t2 | 86/518 (16.6) | 39/266 (14.7) | 47/252 (18.7) | |||||||
| t3 | 125/757 (16.5) | 60/411 (14.6) | 65/346 (18.8) | 24 | ||||||
| t1 | 75/596 (12.6) | 51/333 (15.3) | 24/263 (9.1) | |||||||
| t2 | 64/381 (16.8) | 25/206 (12.1) | 39/175 (22.3) | |||||||
| t3 | 118/596 (19.8) | 56/333 (16.8) | 62/263 (23.6) | 15 | ||||||
| t1 | 25/341 (7.3) | 19/213 (8.9) | 6/128 (4.7) | |||||||
| t2 | 30/208 (14.4) | 12/133 (9.0) | 18/75 (24.0) | |||||||
| t3 | 56/341 (16.4) | 28/213 (13.1) | 28/128 (21.9) | 11 | ||||||
| t1 | 40/296 (13.5) | 34/192 (17.7) | 6/104 (5.8) | |||||||
| t2 | 38/185 (20.5) | 24/114 (21.1) | 14/71 (19.7) | |||||||
| t3 | 52/296 (17.6) | 27/192 (14.1) | 25/104 (24.0) | 10 | ||||||
| t1 | 14/86 (16.3) | 6/34 (17.6) | 8/52 (15.4) | |||||||
| t2 | 14/56 (25.0) | 3/10 (30.0) | 11/46 (23.9) | |||||||
| t3 | 19/86 (22.1) | 9/34 (26.5) | 10/52 (19.2) | −14 | ||||||
| t1 | 48/317 (15.1) | 18/116 (15.5) | 30/201 (14.9) | |||||||
| t2 | 45/245 (18.4) | 14/96 (14.6) | 31/149 (20.8) | |||||||
| t3 | 61/317 (19.2) | 23/116 (19.8) | 38/201 (18.9) | −108 | ||||||
| t1 | 45/313 (14.4) | 28/189 (14.8) | 17/124 (13.7) | |||||||
| t2 | 23/205 (11.2) | 11/119 (9.2) | 12/86 (14.0) | |||||||
| t3 | 55/313 (17.6) | 29/189 (15.3) | 26/124 (21.0) | 18 | ||||||
| t1 | 28/335 (8.4) | 21/197 (10.7) | 7/138 (5.1) | |||||||
| t2 | 24/216 (11.1) | 12/122 (9.8) | 12/94 (12.8) | |||||||
| t3 | 43/335 (12.8) | 25/197 (12.7) | 18/138 (13.0) | 283 | ||||||
| t1 | 68/577 (11.8) | 40/299 (13.4) | 28/278 (10.1) | |||||||
| t2 | 54/411 (13.1) | 23/212 (10.8) | 31/199 (15.6) | |||||||
| t3 | 87/577 (15.1) | 37/299 (12.4) | 50/278 (18.0) | 18 | ||||||
| t1 | 64/363 (17.6) | 34/201 (16.9) | 30/162 (18.5) | |||||||
| t2 | 53/214 (24.8) | 19/105 (18.1) | 34/109 (31.2) | |||||||
| t3 | 91/363 (25.1) | 42/201 (20.9) | 49/162 (30.2) | 11 | ||||||
| t1 | 9/57 (15.8) | 7/34 (20.6) | 2/23 (8.7) | |||||||
| t2 | 14/43 (32.6) | 8/25 (32.0) | 6/18 (33.3) | |||||||
| t3 | 16/57 (28.1) | 9/34 (26.5) | 7/23 (30.4) | 25 | ||||||
| t1 | 3/21 (14.3) | 3/13 (23.1) | 0/8 (0.0) | |||||||
| t2 | 5/15 (33.3) | 2/8 (25.0) | 3/7 (42.9) | |||||||
| t3 | 6/21 (28.6) | 3/13 (23.1) | 3/8 (37.5) | 7 | ||||||
aThe case number at t1 and t3 corresponds to all participants at t3 (N=1353, the basis for the analysis of the primary outcome). For better comparability, only cases are used for t2 that were also present at t3 (N=899).
bThe NNT is 12 if the baseline differences are taken into account.
cAcademic performance was assessed by the students themselves through one single 5-point Likert scale item in the study questionnaire.
Change in smoking prevalence in the intervention and control groups from baseline to 12-month follow-up.
| Pairwise contrasts | Survey wave pairwise contrasts | Contrast estimate | SE | 95% CIb | ||
| Intervention | 12-month follow-up from baseline | 0.015 | 0.015 | 0.975 (883) | .33 | −0.015, 0.045 |
| Control | 12-month follow-up from baseline | 0.096 | 0.018 | 5.413 (714) | <.001 | 0.061, 0.131 |
| Difference in change | Control and intervention groups | 0.081 | 0.023 | 3.456 (1595) | <.001 | 0.035, 0.127 |
aThe sequential Sidak adjusted significance level is .05.
bConfidence interval bounds are approximate.
Nominal and percentage effects of the intervention on the smoking status (secondary outcomes) from baseline to 12-month follow-up (N=1353; P=.001 [Fisher test]).
| Sample | Prospective smoking status (t1-t3) | |||
| Remained a nonsmoker (n=1041) | Started smoking (n=140) | Quit smoking (n=69) | Remained a smoker (n=103) | |
| Control group, n (%) | 460 (75.5) | 82 (13.5) | 22 (3.6) | 45 (7.4) |
| Intervention group, n (%) | 581 (78.1) | 58 (7.8) | 47 (6.3) | 58 (7.8) |
Nominal and percentage effects of the intervention on smoking status by gender.
| Sample | Prospective smoking status (t1-t3) | ||||||||
| Remained a nonsmoker (n=1041) | Started smoking (n=140) | Quit smoking (n=69) | Remained a smoker (n=103) | ||||||
| Total | 460 (75.5) | 82 (13.5) | 22 (3.6) | 45 (7.4) | |||||
| Female | 267 (77.2) | 36 (10.4) | 14 (4.0) | 29 (8.4) | |||||
| Male | 193 (73.4) | 46 (17.5) | 8 (3.0) | 16 (6.1) | |||||
| Total | 581 (78.1) | 58 (7.8) | 47 (6.3) | 58 (7.8) | |||||
| Female | 324 (78.8) | 33 (8.0) | 27 (6.6) | 27 (6.6) | |||||
| Male | 257 (77.2) | 25 (7.5) | 20 (6.0) | 31 (9.3) | |||||
| Female | 591 | 69 | 41 | 56 | |||||
| Male | 450 | 71 | 28 | 47 | |||||
Figure 2Effects of the intervention on smoking status by gender.
Effect of school performance on the change in the prevalence of smoking, calculated with GENLINMIXED.
| Academic performance and treatment | Survey wave pairwise contrasts | Contrast estimate | SE | Adjusted significancea | 95% CIb | ||
| Intervention | 12-month follow-up from baseline | 0.041 | 0.038 | 1.094 (356) | .28 | −0.033, 0.115 | |
| Control | 12-month follow-up from baseline | 0.138 | 0.033 | 4.141 (1155) | <.001 | 0.073, 0.203 | |
| Intervention | 12-month follow-up from baseline | 0.002 | 0.014 | 0.145 (2077) | .89 | −0.026, 0.031 | |
| Control | 12-month follow-up from baseline | 0.077 | 0.020 | 3.936 (754) | <.001 | 0.039, 0.116 | |
aThe sequential Sidak adjusted significance level is .05.
bConfidence interval bounds are approximate.